The U.S. Food and Drug Administration (FDA) recently issued a safety alert regarding cholestasis as a potential adverse reaction to immune checkpoint inhibitors (ICIs) therapy.
However, the underlying mechanisms of ICIs-induced cholestasis remain poorly elucidated.
